On Dec. 16, 2022, Novavax announced that the Standing Committee on Vaccination (STIKO) in Germany had expanded its recommendations for use of Nuvaxovid (NVX-CoV2373) as a COVID-19 booster.

Novavax COVID-19 vaccine was authorized for use as an adult booster in more than 35 countries, and a number of other countries have policy recommendations allowing use of the vaccine as a booster dose.